Dompé Farmaceutici S.P.A.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 4 name spellings.
12
Ending by 2030
Nov 2026
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Nov 30, 2026The maintenance fee for IL-8 inhibitors for use in the treatment of some sarcomas (US 11,660,291) comes due Nov 30, 2026. Unpaid by Jun 1, 2027, it lapses early.
- 1 fee due Jun 17, 2027The maintenance fee for Sulfonamides as GPR40- and GPR120-Agonists (US 10,508,090) comes due Jun 17, 2027. Unpaid by Dec 17, 2027, it lapses early.
- 1 fee due Sep 5, 2027The maintenance fee for Triglyceride Otic Formulations and Uses Thereof (US 11,918,653) comes due Sep 5, 2027. Unpaid by Mar 6, 2028, it lapses early.
- 1 fee due Oct 30, 2027The maintenance fee for Auris Formulations for Treating Otic Diseases and Conditions (US 11,969,501) comes due Oct 30, 2027. Unpaid by May 1, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 19, 2026
- 1 term has ended since Aug 19, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,026,367 | (R)-arylalkylamino derivatives and pharmaceutical compositions containing them In force · From the USPTO record | In force | From the USPTO record | |
| US 8,039,656 | 2-phenylpropionic acid derivatives and pharmaceutical compositions containing them In force · From the USPTO record | In force | From the USPTO record | |
| US 7,652,169 | (2R)-2-[(4-sulfonyl) aminophenyl] propanamides and pharmaceutical compositions containing them In force · From the USPTO record | In force | From the USPTO record | |
| US 7,868,046 | (2R)-2-[(4-sulfonyl) aminophenyl] propanamides and pharmaceutical compositions containing them In force · From the USPTO record | In force | From the USPTO record | |
| US 8,440,711 | 2-aryl-2-fluoropropanoic acids and derivatives and pharmaceutical compositions containing them In force · From the USPTO record | In force | From the USPTO record | |
| US 8,133,911 | (R)-4-(heteroaryl) phenylethyl derivatives and pharmaceutical compositions containing them In force · From the USPTO record | In force | From the USPTO record | |
| US 10,751,281 | Auris Formulations for Treating Otic Diseases and Conditions In force · High confidence | In force | High confidence | |
| US 11,123,285 | Auris Formulations for Treating Otic Diseases and Conditions In force · High confidence | In force | High confidence | |
| US 11,969,501 | Auris Formulations for Treating Otic Diseases and Conditions In force · High confidence | In force | High confidence | |
| US 12,788,714 | Auris Formulations for Treating Otic Diseases and Conditions In force · High confidence | In force | High confidence |
Also on record, not counted in the 42: 16 lapsed for an unpaid fee · 37 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
23 pending · 1 abandoned · 7 no status recorded